<?xml version="1.0" encoding="UTF-8"?><urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9" xmlns:news="http://www.google.com/schemas/sitemap-news/0.9"><url><loc>https://compepharma.com/story/c-1fb366ae65a9f052eb3f</loc><news:news><news:publication><news:name>CompePharma</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-17</news:publication_date><news:title>FDA approves Novartis&#x27; Cosentyx 150 mg for polymyalgia rheumatica</news:title></news:news></url><url><loc>https://compepharma.com/story/c-923471a8d521212250cb</loc><news:news><news:publication><news:name>CompePharma</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-16</news:publication_date><news:title>Gedeon Richter to acquire Mayne Pharma in AUD 604 million cash deal</news:title></news:news></url><url><loc>https://compepharma.com/story/c-5b6d26ddd05ff6bb74a5</loc><news:news><news:publication><news:name>CompePharma</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-16</news:publication_date><news:title>Metagenomi puts hemophilia A editing candidate MGX-001 first in November 2026 deck</news:title></news:news></url><url><loc>https://compepharma.com/story/c-43c45490827deed444e1</loc><news:news><news:publication><news:name>CompePharma</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-16</news:publication_date><news:title>FDA approves Roche&#x27;s Wilserdly with everolimus for ESR1-mutated advanced breast cancer</news:title></news:news></url><url><loc>https://compepharma.com/story/c-3e24df41704ca0c04a0b</loc><news:news><news:publication><news:name>CompePharma</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-16</news:publication_date><news:title>FDA approves Roche&#x27;s oral SERD Wilserdly with everolimus for ESR1-mutated breast cancer</news:title></news:news></url><url><loc>https://compepharma.com/story/c-d2a82d189a1e4b7b30d7</loc><news:news><news:publication><news:name>CompePharma</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-16</news:publication_date><news:title>Kyntra Bio halts FG-3246 prostate cancer work, cuts royalty-financing cap and plans roxadustat MDS Phase 3</news:title></news:news></url><url><loc>https://compepharma.com/story/c-4df3bd1d7b2820819544</loc><news:news><news:publication><news:name>CompePharma</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-16</news:publication_date><news:title>AEON Biopharma gets FDA Type 2b feedback on ABP-450 biosimilar route to BOTOX</news:title></news:news></url><url><loc>https://compepharma.com/story/c-654f1bfaa599d5622ed4</loc><news:news><news:publication><news:name>CompePharma</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-16</news:publication_date><news:title>Lifeloc Q3 revenue rises 12% as SpinDetect drug analyzer launch slips to Q4 2027</news:title></news:news></url><url><loc>https://compepharma.com/story/c-b6ffb9ba6169488e4aa5</loc><news:news><news:publication><news:name>CompePharma</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-16</news:publication_date><news:title>Connect Biopharma reports Q3 loss, plans FDA Phase 3 talks for rademikibart</news:title></news:news></url><url><loc>https://compepharma.com/story/c-973d17d4f46029328817</loc><news:news><news:publication><news:name>CompePharma</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-16</news:publication_date><news:title>Aytu BioPharma to be acquired by Rosemont for about $56M as EXXUA sales grow</news:title></news:news></url><url><loc>https://compepharma.com/story/c-5ed76706ba8a50807ee9</loc><news:news><news:publication><news:name>CompePharma</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-16</news:publication_date><news:title>Merck KGaA to acquire Rapid Micro Biosystems in $0.75-per-share cash tender offer</news:title></news:news></url><url><loc>https://compepharma.com/story/c-65cebbfb38c8d04198c4</loc><news:news><news:publication><news:name>CompePharma</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-16</news:publication_date><news:title>Glass House Brands more than doubles Q3 revenue to $56.8M as net loss narrows</news:title></news:news></url><url><loc>https://compepharma.com/story/c-66759449ec1aac032b74</loc><news:news><news:publication><news:name>CompePharma</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-16</news:publication_date><news:title>20/20 BioLabs Q3 revenue slips to $0.38M; Vermont firefighter cancer screening contract signed</news:title></news:news></url><url><loc>https://compepharma.com/story/c-ca014361991fff40d010</loc><news:news><news:publication><news:name>CompePharma</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-16</news:publication_date><news:title>Glass House Brands reports Q3 2026 results, citing NYSE listing and first CBD biomass sale to Europe</news:title></news:news></url><url><loc>https://compepharma.com/story/c-0554879de61591dbd65b</loc><news:news><news:publication><news:name>CompePharma</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-16</news:publication_date><news:title>ENDRA reports Q3 net loss of $1.5m as Noble Africa merger awaits closing conditions</news:title></news:news></url><url><loc>https://compepharma.com/story/c-c4335d3357529cd998b2</loc><news:news><news:publication><news:name>CompePharma</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-16</news:publication_date><news:title>Merck KGaA to acquire Rapid Micro Biosystems; Q3 revenue rises to $9.5M</news:title></news:news></url><url><loc>https://compepharma.com/story/c-8e1ef866157e4d64419d</loc><news:news><news:publication><news:name>CompePharma</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-16</news:publication_date><news:title>Microbot Medical Q3 revenue falls to $72,000 as gross margin turns negative</news:title></news:news></url><url><loc>https://compepharma.com/story/c-39802c7e0d2a1e04ad6b</loc><news:news><news:publication><news:name>CompePharma</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-16</news:publication_date><news:title>Cerenome reports no dose-limiting toxicities in first 10 patients on repeat intraventricular REYOBIQ</news:title></news:news></url><url><loc>https://compepharma.com/story/c-b3f5093f0e4e19dbb854</loc><news:news><news:publication><news:name>CompePharma</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-16</news:publication_date><news:title>TOYO Co. reports lower Q3 revenue and net income, but higher nine-month sales</news:title></news:news></url><url><loc>https://compepharma.com/story/c-a40b6de6d2f75587dbd0</loc><news:news><news:publication><news:name>CompePharma</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-16</news:publication_date><news:title>China adds Ascentage&#x27;s lisaftoclax to NRDL; olverembatinib coverage renewed after renegotiation</news:title></news:news></url><url><loc>https://compepharma.com/story/c-fa8c3ac9a2b6fa191f4d</loc><news:news><news:publication><news:name>CompePharma</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-16</news:publication_date><news:title>Clearmind completes Part C enrolment in CMND-100 alcohol use disorder trial</news:title></news:news></url><url><loc>https://compepharma.com/story/c-555ee69281fde4a165b5</loc><news:news><news:publication><news:name>CompePharma</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-16</news:publication_date><news:title>Jasper Therapeutics completes IgAN cohort enrolment as Kira deal closes and cash reaches $135.3M</news:title></news:news></url><url><loc>https://compepharma.com/story/c-896143e696a7d3b61f65</loc><news:news><news:publication><news:name>CompePharma</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-16</news:publication_date><news:title>CG Oncology&#x27;s cretostimogene meets Phase 3 PIVOT-006 endpoint in intermediate-risk bladder cancer</news:title></news:news></url><url><loc>https://compepharma.com/story/c-759e2c19c46c004273a7</loc><news:news><news:publication><news:name>CompePharma</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-16</news:publication_date><news:title>Eocene unit and Barcode Nanotech develop tumour-targeted nanoparticle form of Aramchol for liver and GI cancers</news:title></news:news></url><url><loc>https://compepharma.com/story/c-3d80ac99c12131c4d99e</loc><news:news><news:publication><news:name>CompePharma</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-16</news:publication_date><news:title>Aptevo&#x27;s mipletamig triplet yields 79% CR/CRi in TP53-mutated AML; infusion reactions fall</news:title></news:news></url><url><loc>https://compepharma.com/story/c-e1a7043792a701c5a0ab</loc><news:news><news:publication><news:name>CompePharma</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-16</news:publication_date><news:title>Rein Therapeutics releases blinded Phase 2 RENEW lung function data for inhaled LTI-03 in IPF</news:title></news:news></url><url><loc>https://compepharma.com/story/c-ac14460b3841b93308c3</loc><news:news><news:publication><news:name>CompePharma</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-16</news:publication_date><news:title>ALX Oncology reports $147.2M cash, with ALX2004 Phase 1 data due in December</news:title></news:news></url><url><loc>https://compepharma.com/story/c-3e1965c18b8cf9e18b90</loc><news:news><news:publication><news:name>CompePharma</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-16</news:publication_date><news:title>Galectin files belapectin Phase 3 protocol with FDA as chairman converts $105.8M debt</news:title></news:news></url><url><loc>https://compepharma.com/story/c-53a027eb2276493c3d35</loc><news:news><news:publication><news:name>CompePharma</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-16</news:publication_date><news:title>Corbus starts registrational TEMPO-1 trial of Nectin-4 ADC sutantatug envedotin in OPSCC</news:title></news:news></url><url><loc>https://compepharma.com/story/c-830553fe8d6f853a8df8</loc><news:news><news:publication><news:name>CompePharma</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-16</news:publication_date><news:title>Radiopharm&#x27;s 18F-RAD101 PET shows 93.5% MRI agreement in interim Phase 2b brain metastasis data</news:title></news:news></url><url><loc>https://compepharma.com/story/c-8622c4b06cbe662ece51</loc><news:news><news:publication><news:name>CompePharma</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-16</news:publication_date><news:title>Eloxx doses first Alport patients in Phase 2b and wins FDA IND clearance in ADPKD</news:title></news:news></url><url><loc>https://compepharma.com/story/c-a0ab78ecfe0b8616e274</loc><news:news><news:publication><news:name>CompePharma</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-16</news:publication_date><news:title>Apnimed&#x27;s sleep apnoea drug AD109 awaits FDA decision with 28 February 2027 goal date</news:title></news:news></url><url><loc>https://compepharma.com/story/c-31a7944e7b80697816f1</loc><news:news><news:publication><news:name>CompePharma</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-16</news:publication_date><news:title>XORTX completes clinical supply manufacturing for XORLO oxypurinol gout trial XRX-OXY-102</news:title></news:news></url><url><loc>https://compepharma.com/story/c-f2e6f35a760d227636ad</loc><news:news><news:publication><news:name>CompePharma</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-16</news:publication_date><news:title>Adagio Medical&#x27;s VT ablation PMA remains under FDA review as board explores strategic alternatives</news:title></news:news></url><url><loc>https://compepharma.com/story/c-70d1d627479ef29d54ae</loc><news:news><news:publication><news:name>CompePharma</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-16</news:publication_date><news:title>FDA sets 25 March 2027 goal date for Unicycive&#x27;s resubmitted oxylanthanum carbonate application</news:title></news:news></url><url><loc>https://compepharma.com/story/c-18fcea9b95431e229d06</loc><news:news><news:publication><news:name>CompePharma</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-16</news:publication_date><news:title>FDA grants orphan drug designation to Noema&#x27;s basimglurant for trigeminal neuralgia</news:title></news:news></url><url><loc>https://compepharma.com/story/c-28104071906c1b31c2c3</loc><news:news><news:publication><news:name>CompePharma</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-16</news:publication_date><news:title>Sono Group updates share counts ahead of 11 December redomiciliation vote</news:title></news:news></url><url><loc>https://compepharma.com/story/c-5e21f9715c9570f09ec0</loc><news:news><news:publication><news:name>CompePharma</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-16</news:publication_date><news:title>Mentari Therapeutics reports $63.0M nine-month net loss, backed by related-party note</news:title></news:news></url><url><loc>https://compepharma.com/story/c-317c9442f6cc06467a3d</loc><news:news><news:publication><news:name>CompePharma</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-16</news:publication_date><news:title>FDA issues complete response letter for Summit&#x27;s ivonescimab in EGFR-mutant NSCLC</news:title></news:news></url><url><loc>https://compepharma.com/story/c-3320c2b155512e929bee</loc><news:news><news:publication><news:name>CompePharma</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-16</news:publication_date><news:title>InMed completes Mentari merger and renames itself Mentari Therapeutics, with PACAP migraine antibody in Phase 1</news:title></news:news></url><url><loc>https://compepharma.com/story/c-a78d592e98f944dfda33</loc><news:news><news:publication><news:name>CompePharma</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-16</news:publication_date><news:title>Rejuvenate Biomed completes last patient visit in Phase 2 MINT-COPD trial of RJx-01</news:title></news:news></url><url><loc>https://compepharma.com/story/c-19eaa448c8f3b8a83c79</loc><news:news><news:publication><news:name>CompePharma</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-16</news:publication_date><news:title>FDA grants Breakthrough Therapy status to daretabart for newly diagnosed high-risk neuroblastoma in children</news:title></news:news></url><url><loc>https://compepharma.com/story/c-f5cc98f29ab8cd58b7c6</loc><news:news><news:publication><news:name>CompePharma</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-16</news:publication_date><news:title>Lakefront Biotherapeutics launches second €50m share buyback after completing first programme</news:title></news:news></url><url><loc>https://compepharma.com/story/o-3496d8b2bf96e063</loc><news:news><news:publication><news:name>CompePharma</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-16</news:publication_date><news:title>Greek regulator EOF orders market recall of non-sterile zig-zag cotton gauze roll</news:title></news:news></url><url><loc>https://compepharma.com/insights/2026-11-17-rosemont-s-56m-aytu-bid-shows-buyers-paying-for-growing-launches-not-pipelines</loc><news:news><news:publication><news:name>CompePharma</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-17</news:publication_date><news:title>Rosemont&#x27;s $56M Aytu bid shows buyers paying for growing launches, not pipelines</news:title></news:news></url><url><loc>https://compepharma.com/insights/2026-11-17-cormedix-q3-post-tdapa-defencath-reset-meets-heron-deal-and-a-suspended-2027-out</loc><news:news><news:publication><news:name>CompePharma</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-17</news:publication_date><news:title>CorMedix Q3: Post-TDAPA DefenCath Reset Meets Heron Deal and a Suspended 2027 Outlook</news:title></news:news></url><url><loc>https://compepharma.com/insights/2026-11-16-view-adjusted-ebitda-is-the-headline-number-this-earnings-season-shows-why-the-bridge</loc><news:news><news:publication><news:name>CompePharma</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-16</news:publication_date><news:title>Adjusted EBITDA is the headline number. This earnings season shows why the bridge matters more</news:title></news:news></url><url><loc>https://compepharma.com/insights/2026-11-16-iambic-s-q3-ai-platform-deals-double-revenue-but-the-clinic-drives-the-burn</loc><news:news><news:publication><news:name>CompePharma</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-16</news:publication_date><news:title>Iambic&#x27;s Q3: AI-platform deals double revenue, but the clinic drives the burn</news:title></news:news></url><url><loc>https://compepharma.com/insights/2026-11-16-vir-s-follow-on-tests-whether-open-equity-windows-favor-platform-stories-over-sm</loc><news:news><news:publication><news:name>CompePharma</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-16</news:publication_date><news:title>Vir&#x27;s Follow-On Tests Whether Open Equity Windows Favor Platform Stories Over Small-Cap Fixes</news:title></news:news></url><url><loc>https://compepharma.com/insights/2026-11-16-view-the-real-divide-this-earnings-season-is-runway-who-sets-the-timeline-and-who-is</loc><news:news><news:publication><news:name>CompePharma</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-16</news:publication_date><news:title>The real divide this earnings season is runway: who sets the timeline, and who is set by it</news:title></news:news></url><url><loc>https://compepharma.com/insights/2026-11-16-tenon-medical-s-15-6m-raise-clears-convertibles-and-nasdaq-risk-but-not-the-fund</loc><news:news><news:publication><news:name>CompePharma</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-16</news:publication_date><news:title>Tenon Medical&#x27;s $15.6M raise clears convertibles and Nasdaq risk, but not the funding question</news:title></news:news></url><url><loc>https://compepharma.com/insights/2026-11-16-alumis-posts-narrower-q3-loss-as-nda-nears-but-a-lupus-miss-narrows-envudeucitin</loc><news:news><news:publication><news:name>CompePharma</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-16</news:publication_date><news:title>Alumis posts narrower Q3 loss as NDA nears, but a lupus miss narrows envudeucitinib&#x27;s path</news:title></news:news></url><url><loc>https://compepharma.com/insights/2026-11-16-im-cannabis-funds-a-shrinking-business-with-converts-while-peers-raise-on-scale</loc><news:news><news:publication><news:name>CompePharma</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-16</news:publication_date><news:title>IM Cannabis funds a shrinking business with converts while peers raise on scale and strategics</news:title></news:news></url><url><loc>https://compepharma.com/insights/2026-11-16-view-litigation-is-a-launch-cost-and-earnings-season-is-finally-pricing-it-that-way</loc><news:news><news:publication><news:name>CompePharma</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-16</news:publication_date><news:title>Litigation is a launch cost, and earnings season is finally pricing it that way</news:title></news:news></url><url><loc>https://compepharma.com/insights/2026-11-16-femasys-s-30m-placement-funds-a-u-s-launch-and-a-pivotal-trial-as-sales-slip-44</loc><news:news><news:publication><news:name>CompePharma</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-16</news:publication_date><news:title>Femasys&#x27;s $30M placement funds a U.S. launch and a pivotal trial as sales slip 44.5%</news:title></news:news></url><url><loc>https://compepharma.com/insights/2026-11-16-ionis-lowers-tryngolza-outlook-to-50m-as-dawnzera-and-partners-carry-q3</loc><news:news><news:publication><news:name>CompePharma</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-16</news:publication_date><news:title>Ionis lowers TRYNGOLZA outlook to ~$50M as DAWNZERA and partners carry Q3</news:title></news:news></url><url><loc>https://compepharma.com/insights/2026-11-15-view-a-guidance-raise-is-only-as-good-as-who-controls-the-trigger</loc><news:news><news:publication><news:name>CompePharma</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-15</news:publication_date><news:title>A guidance raise is only as good as who controls the trigger</news:title></news:news></url><url><loc>https://compepharma.com/insights/2026-11-15-keenova-s-acthar-and-xiaflex-lift-guidance-but-the-quarter-still-ends-in-a-96m-l</loc><news:news><news:publication><news:name>CompePharma</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-15</news:publication_date><news:title>Keenova&#x27;s Acthar and XIAFLEX lift guidance, but the quarter still ends in a $96M loss</news:title></news:news></url><url><loc>https://compepharma.com/insights/2026-11-15-colospan-s-greece-cyprus-cg-100-deal-shows-a-capital-light-route-into-europe</loc><news:news><news:publication><news:name>CompePharma</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-15</news:publication_date><news:title>Colospan&#x27;s Greece-Cyprus CG-100 deal shows a capital-light route into Europe</news:title></news:news></url><url><loc>https://compepharma.com/insights/2026-11-15-view-medicare-s-open-wallet-comes-with-a-ledger-build-the-paper-trail-before-volume</loc><news:news><news:publication><news:name>CompePharma</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-15</news:publication_date><news:title>Medicare&#x27;s open wallet comes with a ledger: build the paper trail before volume</news:title></news:news></url><url><loc>https://compepharma.com/insights/2026-11-15-alcon-pairs-5-q3-sales-growth-with-a-neurotech-purchase-as-eye-care-dealmaking-w</loc><news:news><news:publication><news:name>CompePharma</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-15</news:publication_date><news:title>Alcon pairs 5% Q3 sales growth with a Neurotech purchase as eye-care dealmaking widens</news:title></news:news></url><url><loc>https://compepharma.com/insights/2026-11-15-organogenesis-q3-revenue-falls-70-as-cost-cuts-fail-to-keep-pace-and-cash-drops</loc><news:news><news:publication><news:name>CompePharma</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-15</news:publication_date><news:title>Organogenesis Q3: revenue falls 70% as cost cuts fail to keep pace, and cash drops to $26.9M</news:title></news:news></url><url><loc>https://compepharma.com/insights/2026-11-15-charles-river-s-470m-frontage-carve-out-buys-bioanalysis-depth-through-a-take-pr</loc><news:news><news:publication><news:name>CompePharma</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-15</news:publication_date><news:title>Charles River&#x27;s $470m Frontage Carve-Out Buys Bioanalysis Depth Through a Take-Private</news:title></news:news></url><url><loc>https://compepharma.com/insights/2026-11-15-view-defined-demand-scales-fast-new-paradigms-don-t-budget-launches-accordingly</loc><news:news><news:publication><news:name>CompePharma</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-15</news:publication_date><news:title>Defined demand scales fast; new paradigms don&#x27;t. Budget launches accordingly</news:title></news:news></url><url><loc>https://compepharma.com/insights/2026-11-15-cormedix-s-222-6m-heron-deal-buys-a-four-product-hospital-pain-and-nausea-portfo</loc><news:news><news:publication><news:name>CompePharma</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-15</news:publication_date><news:title>CorMedix&#x27;s $222.6M Heron Deal Buys a Four-Product Hospital Pain and Nausea Portfolio</news:title></news:news></url><url><loc>https://compepharma.com/insights/2026-11-15-zymeworks-250m-ziihera-milestone-lifts-q3-and-guidance-but-the-base-business-is</loc><news:news><news:publication><news:name>CompePharma</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-15</news:publication_date><news:title>Zymeworks&#x27; $250M Ziihera milestone lifts Q3 and guidance, but the base business is still being built</news:title></news:news></url></urlset>